CLSD / Clearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript

For the extreme gambler who has done homework regarding risk and rewards, few thrills excite as much as cheap stocks to buy under $1. By logical deduc more_horizontal

ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delive more_horizontal

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the deliver more_horizontal

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compa more_horizontal

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery more_horizontal

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relati more_horizontal

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. more_horizontal

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief more_horizontal